MD/PhD students from the Carle Illinois College of Medicine are pioneering advancements in medical technology and surgical procedures. Their training merges engineering and medical expertise, enabling them to tackle complex health challenges through innovative solutions, including AI applications and surgical robotics.

## Illinois MD/PhD Students Drive Innovation in Medicine and Robotics

MD/PhD students at the Carle Illinois College of Medicine (CI MED) are at the forefront of transforming healthcare by integrating medical and engineering disciplines.

This unique approach prepares these future Physician Innovators to confront significant medical challenges with innovative solutions, particularly in fields like surgical robotics and artificial intelligence (AI).

The Medical Scholars Program (MSP) at CI MED combines rigorous medical education with extensive research opportunities at the University of Illinois Urbana-Champaign.

This dual-degree program not only equips students with clinical skills but also fosters a deep understanding of engineering principles, allowing them to develop new technologies and methodologies for patient care.

Dr Dan Llano, the MSP Director, emphasizes the importance of cross-disciplinary training, stating, "We want graduates who don't just adapt to the future of health care; they help design it." This philosophy is reflected in the projects being undertaken by students, who are already making strides in addressing issues such as heart and kidney diseases, neurological injuries, and access to care.

One of the notable areas of focus for these students is surgical robotics.

At institutions like Loyola Medicine, advances in technology are revolutionizing how surgical procedures are performed.

The use of mixed reality in shoulder surgeries allows surgeons to overlay 3D holograms onto the surgical field, providing real-time insights into a patient's anatomy.

This innovation has led to more precise surgeries and improved patient outcomes.

For instance, Dr Dane Salazar recently utilized this technology during a total shoulder replacement surgery, resulting in a significant recovery for the patient, who returned to normal activities pain-free.

Such advancements demonstrate how integrating engineering with medicine can yield transformative results for patients, enhancing both the surgical process and recovery experiences.

Beyond surgical innovations, Illinois MD/PhD students are also addressing critical issues in cancer care.

The University of Chicago Medicine is investing heavily in cancer research and treatment facilities, with plans for an $815 million cancer pavilion.

This facility will consolidate various cancer services, improving patient access and care quality while facilitating groundbreaking research.

As the second-leading cause of death in the US, cancer presents significant challenges, particularly in underserved communities.

The new pavilion aims to tackle these challenges by providing comprehensive cancer care that combines state-of-the-art facilities with research-driven treatment protocols.

AI applications are another critical area where Illinois MD/PhD students are making a difference.

The integration of AI into healthcare has the potential to improve diagnostics, treatment personalization, and patient monitoring.

With their training, these students are positioned to lead the development of AI-driven tools that enhance patient care and medical research.

The emphasis on innovation ensures that graduates from the MSP program will be prepared to navigate and influence the evolving landscape of healthcare.

By cultivating a new generation of clinician-scientists, CI MED aims to bridge the gap between medical practice and technological advancement, ultimately improving patient outcomes.

As Illinois MD/PhD students tackle some of medicine's toughest challenges, their work exemplifies the power of interdisciplinary collaboration.

By merging engineering innovation with medical expertise, they are not only preparing to advance their own careers but also to enhance the future of healthcare.

The ongoing commitment to research and innovation at institutions like CI MED promises to yield significant advancements in surgical practices, cancer treatment, and AI applications, ultimately benefiting patients and communities alike.

With groundbreaking projects underway and a focus on developing the next generation of medical leaders, Illinois is positioning itself as a hub for medical innovation, where the future of healthcare is being shaped by the minds of today’s students.

Illinois MD/PhD Students Drive Innovation in Medicine and Robotics

illinois-md-phd-students-drive-innovation-in-medicine-and-robotics

The FDA has revised its guidelines for the Breakthrough Devices Program, emphasizing the importance of health equity and accessibility in device designation. This evolution reflects a broader understanding of how medical technologies can address healthcare disparities while ensuring patient safety and efficacy.

## FDA's Updated Criteria for Breakthrough Device Designation

The US Food and Drug Administration (FDA) has been revising its framework for what constitutes a 'breakthrough' medical device, aiming to expedite access to innovative technologies that can significantly improve patient outcomes.

The Breakthrough Devices Program (BDP), initiated under the 21st Century Cures Act of 2016, allows certain medical devices that meet specific criteria to receive prioritized review, potentially leading to faster market authorization.

Under the revised guidelines released on September 15, 2023, the FDA is now considering a medical device's potential to address health and healthcare disparities as part of its evaluation criteria.

This marks a significant shift in the FDA's perspective, highlighting the agency's commitment to improving access to effective healthcare solutions for diverse populations.

To qualify for breakthrough designation, a device must provide more effective treatment or diagnosis for life-threatening or severely debilitating conditions and meet at least one of four secondary criteria.

These include representing breakthrough technology, offering significant advantages over existing treatments, addressing an unmet medical need, or being in the best interest of patients.

The BDP aims to facilitate quicker development and review processes while maintaining rigorous standards for safety and effectiveness.

However, as of June 30, 2023, only about 9.6% of devices designated as breakthrough have received marketing authorization, indicating challenges in meeting the necessary evidence requirements.

The FDA's recent updates place greater importance on how devices can improve health equity.

For example, the agency may consider whether a device's design enhances accessibility for disadvantaged populations, thereby increasing its potential to deliver effective treatments.

This evolution in criteria reflects a broader understanding of how social determinants of health can impact treatment outcomes and patient access to care.

One recent example of a medical device that exemplifies this shift is the EvoLiver test, which received breakthrough designation for its ability to detect hepatocellular carcinoma in high-risk cirrhosis patients.

The test boasts a significantly higher sensitivity compared to traditional methods, potentially transforming liver cancer surveillance and improving access to timely treatment.

### Regulatory Challenges and Opportunities

While the BDP aims to accelerate innovation, it is not without challenges.

The FDA's recent guidance underscores the need for manufacturers to showcase how their devices address disparities and improve outcomes for specific populations.

This focus on health equity may necessitate changes in clinical trial designs to ensure diverse representation of patients.

Moreover, the Centers for Medicare & Medicaid Services (CMS) has proposed repealing the Medicare Coverage of Innovative Technology and Definition of "Reasonable and Necessary" rule, which previously aimed to provide expedited coverage for breakthrough devices.

The CMS argues that the FDA's safety and effectiveness standards alone are insufficient for guaranteeing Medicare coverage, highlighting the need for robust clinical data relevant to the Medicare population.

This potential repeal raises concerns about the accessibility of breakthrough devices for Medicare beneficiaries, as it may slow the introduction of innovative technologies into the healthcare system.

The CMS has stated that while the MCIT/R&N rule was intended to enhance access, it could lead to coverage decisions without adequate evidence of a product's necessity for specific patient populations.

The FDA's evolving view on what defines a breakthrough device reflects a growing recognition of the complexities surrounding healthcare access and equity.

By emphasizing the importance of addressing health disparities, the agency is paving the way for a more inclusive approach to medical device innovation.

As these changes unfold, it will be crucial for manufacturers to adapt to the new criteria and ensure that their products meet both regulatory and patient needs in a rapidly evolving healthcare landscape.

The impact of these changes will likely continue to shape the future of medical device development and access, affecting stakeholders from manufacturers to healthcare providers and patients alike.

As the FDA and CMS navigate these regulatory waters, the goal remains clear: to enhance patient care through timely access to life-saving technologies while ensuring that all populations benefit equally from advancements in medical science.

FDA's Updated Criteria for Breakthrough Device Designation

fda-s-updated-criteria-for-breakthrough-device-designation

Long COVID affects millions, altering lives and challenging healthcare systems. As awareness grows, stories from patients reveal the complexities of this chronic condition, highlighting the urgent need for better understanding and support.

## Living With Long COVID: The Invisible Challenge of Recovery

Long COVID has emerged as a significant public health challenge since the onset of the COVID-19 pandemic.

Affecting approximately 6 to 7% of adults who have had acute COVID-19 symptoms, it is estimated that around 400 million people worldwide have experienced long-lasting effects since the pandemic began in 2019.

The condition presents a confusing array of symptoms that can persist long after the initial infection, leading to considerable disruption in daily life and raising urgent questions about effective treatments and support systems.

Patients with long COVID often describe their experiences as life-altering.

For many, the initial infection may have seemed mild, with symptoms such as fever and fatigue, yet the aftermath can include severe fatigue, cognitive dysfunction, and cardiovascular issues that radically change their quality of life.

The lack of objective medical tests to validate these symptoms often leads to disbelief and stigma from society and even healthcare providers, further complicating recovery for those affected.

The individual stories of long COVID patients reveal the profound emotional and social impacts of the condition.

For instance, Elle Seibert, a 31-year-old living with long COVID, expressed the emotional toll and isolation that comes with the illness, stating, "You're realizing how easily society at large and people in your life will abandon you when you cannot offer them things".

Similarly, Lawrence Totress, who experienced debilitating cognitive symptoms following a COVID-19 infection, described his struggles with memory and daily tasks, illustrating how long COVID can lead to profound changes in identity and social roles.

Research into long COVID has been significantly driven by patient-led initiatives and online communities, which have provided invaluable insights into the lived experiences of those suffering from the condition.

These communities have emphasized the need for validation of symptoms and the importance of alternative therapies, as traditional healthcare systems often fail to address the complexities of long COVID adequately.

The scientific community has also begun to recognize the multifaceted nature of long COVID.

Studies indicate that the condition can present with symptoms affecting multiple organ systems, often manifesting as fatigue, pain, and cognitive issues often referred to as "brain fog".

The persistence of SARS-CoV-2 particles in some patients' blood has been linked to ongoing inflammation, further complicating the understanding and treatment of the condition.

Notably, women, individuals of Hispanic origin, and those with severe initial infections appear to be at higher risk for developing long COVID, although symptoms can arise from even mild cases.

Despite growing recognition of long COVID as a serious health issue, access to appropriate medical care and support remains inconsistent.

Many patients report difficulties in obtaining disability benefits, highlighting the need for improved pathways to support those affected by long COVID.

The Los Angeles County Department of Public Health has initiated efforts to study policies and services to assist long COVID patients, yet significant gaps in care and understanding persist within the healthcare system.

As the conversation surrounding long COVID continues to evolve, advocates are calling for increased funding and research to better understand the condition, emphasizing the need for a patient-centered approach.

The Long COVID Moonshot initiative, which seeks $1 billion in annual research funding, aims to highlight the urgency of addressing the long-term impacts of COVID-19 on individuals and society.

With the ongoing circulation of the virus, new cases of long COVID continue to emerge, underscoring the critical need for public health strategies that recognize this chronic condition as a long-term consequence of the pandemic.

As healthcare systems grapple with the complexities of long COVID, collaboration between patients, healthcare providers, and researchers will be essential in developing effective treatments and support frameworks to improve the lives of millions living with this invisible illness.

In conclusion, long COVID represents not only a medical challenge but a profound social issue that affects the fabric of many lives.

By listening to patient experiences and prioritizing research, society can begin to address the urgent needs of those affected, paving the way for a more inclusive approach to health and recovery in the post-pandemic world.

Living With Long COVID: The Invisible Challenge of Recovery

living-with-long-covid-the-invisible-challenge-of-recovery

Health systems are increasingly focusing on measuring the return on investment (ROI) for AI tools beyond just financial metrics. By leveraging data-driven methodologies, organizations aim to assess both clinical outcomes and operational efficiencies, ensuring that AI enhances patient care while addressing financial pressures.

## Assessing ROI for AI Tools in Healthcare: A Strategic Approach

Health systems are navigating the complex landscape of artificial intelligence (AI) to enhance patient care and improve operational efficiency.

As AI tools become more prevalent, determining their return on investment (ROI) is critical.

However, a traditional financial perspective is proving inadequate for capturing the full impact of these technologies on healthcare delivery.

Healthcare executives are recognizing that a narrow focus on cost savings and revenue generation fails to account for the broader clinical benefits that AI can provide.

According to industry experts, the evaluation of AI solutions should prioritize clinical outcomes, safety, and quality, rather than solely financial returns.

### The Shift Towards Comprehensive ROI Assessment

Michael Meucci, CEO of Arcadia, emphasizes that health systems should first analyze their own data to identify inefficiencies before investing in AI tools.

This data-driven approach allows organizations to target specific areas for improvement, thus ensuring that the AI solutions they choose will address their unique challenges.

Financial pressures within the healthcare sector are forcing organizations to adopt more rigorous measurement frameworks for evaluating AI's impact.

Providers are increasingly aware that tools which improve clinician satisfaction and reduce administrative burdens, even if they do not directly generate obvious financial returns, contribute significant value.

For instance, ambient documentation tools can alleviate burnout among physicians, leading to enhanced retention rates and potential cost savings associated with reduced turnover.

To accurately measure ROI, health systems are developing structured methodologies that incorporate both tangible and intangible benefits.

Abridge, a generative AI company, has been working with numerous health systems to create a measurement framework that evaluates the ROI impact of ambient AI tools.

Their approach involves custom SQL queries that allow for a detailed analysis of various metrics, including clinician workload, efficiency, and patient outcomes.

For example, Sharp HealthCare reported an increase in work relative value units (wRVUs) per encounter after implementing AI technology, indicating improved documentation and care delivery.

Similarly, MaineHealth experienced a significant reduction in time spent on clinical notes, highlighting how AI can streamline workflows and enhance clinician efficiency.

While evaluating ROI, health systems must also consider the risks associated with AI implementations.

A comprehensive risk assessment framework developed by the Cybersecurity and Infrastructure Security Agency (CISA) and the National Institute of Standards and Technology (NIST) outlines various domains that contribute to the overall risk of AI tools.

These include clinical documentation accuracy, patient safety, and data integrity, which are crucial for maintaining trust in AI systems.

Moreover, organizations are encouraged to adopt a multidimensional ROI model that encompasses clinical impact, operational efficiency, ethical considerations, and financial outcomes.

This holistic framework allows health systems to connect AI's clinical benefits to their financial performance, ensuring that investments in technology yield meaningful results.

The healthcare sector is beginning to recognize the limitations of traditional ROI models, which often overlook the long-term clinical improvements AI can foster.

For instance, AI tools that enhance predictive analytics for patient deterioration can lead to significant cost savings by reducing the lengths of hospital stays and improving overall patient outcomes.

Health systems are urged to develop metrics that assess the quality of care alongside financial implications.

This includes considering factors such as quality-adjusted life years (QALYs) and patient-reported outcome measures (PROMs), which can provide a more comprehensive view of the value AI brings to healthcare.

### Conclusion: A Strategic Investment in AI

In conclusion, as health systems increasingly adopt AI technologies, the focus must shift from merely assessing financial ROI to a more responsible and comprehensive evaluation of their impacts.

By integrating rigorous measurement frameworks that capture clinical outcomes, operational efficiencies, and patient satisfaction, organizations can make informed decisions about their AI investments.

Ultimately, this strategic approach will enable healthcare providers to leverage AI tools effectively, ensuring that they not only meet financial goals but also enhance the quality of care delivered to patients.

With the right frameworks in place, health systems can navigate the complexities of AI investment, maximizing both clinical and financial returns in an evolving healthcare landscape.

Assessing ROI for AI Tools in Healthcare: A Strategic Approach

assessing-roi-for-ai-tools-in-healthcare-a-strategic-approach

Insilico Medicine has signed a landmark $2.75 billion agreement with Eli Lilly to develop drugs using AI technology. This partnership, which includes an upfront payment of $115 million, aims to expand the pharmaceutical giant's capabilities in drug discovery and development.

## Insilico Medicine and Eli Lilly Forge $2.75 Billion AI Drug Deal

Insilico Medicine, a Hong Kong-based biotechnology company, has entered into a significant collaboration with US pharmaceutical leader Eli Lilly, valued at up to $2.75 billion.

This agreement marks a deepening of their partnership, building on previous collaborations focused on artificial intelligence (AI) in drug discovery and development.

As part of the deal, Insilico will receive an upfront payment of $115 million, with additional funds contingent on meeting various regulatory and commercial milestones.

Insilico’s CEO, Alex Zhavoronkov, noted that this financial structure reflects the potential of their AI-driven drug candidates.

The collaboration allows Eli Lilly to obtain exclusive worldwide rights to develop, manufacture, and commercialize certain oral therapeutics identified through Insilico's AI platform.

This partnership is expected to enhance Lilly's access to innovative therapeutic candidates across multiple disease areas.

Insilico Medicine has already developed at least 28 drugs using generative AI tools, with nearly half of these candidates currently in clinical trials.

This collaboration is anticipated to accelerate the identification of promising therapeutic options and leverage the strengths of both companies in AI and drug development.

Zhavoronkov has expressed admiration for Eli Lilly, stating that the pharmaceutical company has superior capabilities in areas of AI compared to his own firm.

He praised Lilly's expertise and expressed excitement about the opportunities this partnership presents for developing new drugs.

Eli Lilly has been proactive in integrating AI into its operations, previously partnering with Nvidia to build a powerful supercomputer aimed at enhancing molecule discovery research.

This technological advancement is part of Lilly’s broader strategy to improve efficiency in drug development processes.

The partnership follows a prior AI software licensing agreement between the two companies, initiated in 2023.

This earlier collaboration set the foundation for the current deal, demonstrating the growing trend of integrating AI into pharmaceutical research and development.

The recent agreement is also aligned with Insilico's goal of targeting diseases with significant unmet medical needs, leveraging advanced AI algorithms to identify multi-purpose targets.

Insilico Medicine, founded in 2014, has rapidly gained recognition in the biopharma sector for its innovative approach to drug discovery.

The company aims to provide alternatives to traditional animal testing by using AI to predict how various compounds affect cellular systems.

This emphasis on AI-driven solutions positions Insilico as a sought-after partner in the industry.

The collaboration with Eli Lilly is expected to be mutually beneficial, allowing both companies to combine their strengths in AI and clinical development.

As they work together on these promising therapeutics, they aim to make significant strides in addressing complex health challenges across a variety of diseases.

Overall, the $2.75 billion deal between Insilico Medicine and Eli Lilly represents a significant advancement in the application of AI in drug development.

By harnessing the power of AI, the partnership aims to accelerate the discovery of new treatments and improve patient outcomes in the future.

Insilico Medicine and Eli Lilly Forge $2.75 Billion AI Drug Deal

insilico-medicine-and-eli-lilly-forge-2-75-billion-ai-drug-deal

The US FDA has granted Breakthrough Therapy designation to Wugen's CAR-T cell therapy, WU-CART-007, aimed at treating aggressive T-cell cancers. Developed at Washington University, this therapy shows promising early results in clinical trials, offering hope to patients with limited treatment options.

## FDA Grants Breakthrough Therapy Status to Innovative CAR-T Cell Therapy

The US Food and Drug Administration (FDA) has officially granted Breakthrough Therapy designation to a novel CAR-T cell therapy known as WU-CART-007, aimed at treating aggressive T-cell malignancies.

This innovative therapy, developed by researchers at Washington University School of Medicine in St.

Louis, represents a significant advancement in the treatment of rare and challenging blood cancers, specifically T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL).

Breakthrough Therapy designation is designed to expedite the development and review of therapies for serious or life-threatening conditions, especially when preliminary clinical evidence suggests substantial improvement over existing treatments.

The FDA’s decision was based on promising early-phase clinical trial results that indicated WU-CART-007 can effectively target and eliminate cancerous T cells with manageable side effects.

Approximately 1,000 individuals in the US are diagnosed annually with T-cell cancers, which often have poor outcomes.

For patients whose cancer does not respond to initial treatments or relapses after therapy, survival rates are grim, typically averaging six months.

Less than 7% of these patients are alive five years post-diagnosis.

DiPersio, an oncologist at WashU Medicine and the first developer of the therapy, expressed optimism about its potential to improve long-term survival rates for this patient population.

He highlighted that WU-CART-007 could enable patients to proceed to stem cell transplantation, the only curative option available, which many do not qualify for due to their condition prior to achieving remission.

The therapy is noteworthy for its "off-the-shelf" availability, meaning it can be prepared in advance from healthy donor cells rather than requiring a tailored product for each patient.

This approach significantly reduces the time it takes to administer the treatment, which is crucial for patients with aggressive cancers who cannot afford to wait for individualized therapies to be prepared, a process that can take weeks.

Clinical trials for WU-CART-007 have demonstrated an overall response rate of 91% in patients evaluated after treatment, with a complete remission rate of 72.7% among those who could be assessed.

Among the patients who underwent subsequent stem cell transplants, several have remained in remission with no signs of disease six to twelve months later, according to data published in the journal Blood.

The ongoing Phase 2 trial, known as T-RRex, is further evaluating the therapy's safety and efficacy in patients with relapsed or refractory T-ALL and T-LL.

This study is being conducted across multiple centers in the US, Australia, and Europe, reinforcing the global interest in this groundbreaking treatment option.

In addition to its innovative approach, Wugen, the biotechnology company licensed to develop this therapy, has received multiple designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations.

These classifications help streamline the development process further, allowing for closer collaboration with regulatory authorities to expedite patient access to promising therapies.

As the healthcare landscape continues to evolve, the approval of WU-CART-007 highlights the potential of CAR-T cell therapies to transform treatment paradigms for patients with aggressive blood cancers, offering hope where options have historically been limited.

The research and clinical efforts at WashU Medicine, particularly through the Siteman Cancer Center, underscore the commitment to advancing innovative cancer therapies that could improve patient outcomes in the future.

The medical community remains hopeful that with the completion of ongoing studies, WU-CART-007 could soon emerge as a critical tool in the fight against T-cell malignancies, potentially saving lives and improving the quality of care for affected patients.

FDA Grants Breakthrough Therapy Status to Innovative CAR-T Cell Therapy

fda-grants-breakthrough-therapy-status-to-innovative-car-t-cell-therapy

A multistate outbreak of E. coli O157:H7 infections has been linked to RAW FARM-brand raw cheddar cheese, with nine confirmed cases reported as of March 2026. The CDC and FDA are advising consumers to avoid these products due to severe health risks, particularly for young children.

## Ongoing E. coli O157:H7 Outbreak Linked to RAW FARM Cheddar Cheese

coli O157:H7 infections has emerged, connected to RAW FARM-brand raw cheddar cheese.

As of March 26, 2026, the Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration (FDA) have confirmed nine cases across three states, primarily affecting children under the age of five .

Epidemiological investigations indicate that all individuals reported consuming RAW FARM-brand cheese or other raw dairy products in the week prior to their illness.

Of the nine reported cases, three individuals have been hospitalized, and one developed hemolytic uremic syndrome (HUS), a severe condition that can result in kidney failure.

Fortunately, no fatalities have been recorded thus far .

The outbreak has primarily impacted California, with five confirmed cases, while Florida and Texas have reported fewer cases.

Public health officials note that the actual number of infections may be higher than reported due to underdiagnosis, as many affected individuals do not seek medical care or undergo testing for E.

Health officials are particularly concerned about the potential for severe illness among vulnerable populations.

coli infection include severe stomach cramps, diarrhea (which may be bloody), fever, nausea, and vomiting.

These symptoms typically manifest three to four days after exposure to the bacteria, with most individuals recovering within a week.

However, some cases can lead to serious complications, especially in young children, older adults, and those with weakened immune systems .

In light of the ongoing investigation, the FDA and CDC have issued clear recommendations.

Consumers are advised not to eat or serve RAW FARM-brand raw cheddar cheese and to dispose of any such products immediately.

Furthermore, it is crucial to clean and sanitize any surfaces or utensils that may have come into contact with the cheese to prevent cross-contamination .

Retailers and food service providers are also urged to refrain from selling or serving RAW FARM-brand products until further notice.

The FDA has recommended a voluntary recall of these products; however, RAW FARM, LLC has not complied with this recommendation as of the latest updates, raising concerns about public safety .

The investigation remains active, with public health officials conducting interviews and collecting data to trace the outbreak's source.

Whole genome sequencing has confirmed that the E.

coli strains isolated from ill individuals are genetically related, suggesting a common source of contamination.

The FDA has initiated inspections at RAW FARM facilities, although no positive tests for E.

coli have been reported in products manufactured during the outbreak period .

Public health authorities emphasize the importance of consumer awareness regarding food safety, especially concerning raw dairy products.

They recommend choosing pasteurized dairy options to mitigate the risk of infection from harmful bacteria such as E.

For the latest updates on this outbreak, the CDC and FDA have provided resources for consumers and health care providers.

Individuals experiencing symptoms consistent with E.

coli infection after consuming RAW FARM-brand products are advised to consult their health care provider immediately .

Public health officials continue to monitor and investigate this outbreak, working closely with state and federal partners to prevent further illnesses.

Topic

Medicine

Recent articles:

FDA's Updated Criteria for Breakthrough Device Designation

Living With Long COVID: The Invisible Challenge of Recovery

Assessing ROI for AI Tools in Healthcare: A Strategic Approach

Insilico Medicine and Eli Lilly Forge $2.75 Billion AI Drug Deal

FDA Grants Breakthrough Therapy Status to Innovative CAR-T Cell Therapy

Ongoing E. coli O157:H7 Outbreak Linked to RAW FARM Cheddar Cheese

State Legislation to Enhance Medicaid Mental Health Support

Revolutionary CAR-T Cell Therapy Receives FDA Breakthrough Designation

Rocket Pharmaceuticals Secures FDA Approval for Kresladi Therapy

Nonbinary Doctor Sues NYC Health for Alleged Discrimination

Transforming Mental Health Care Access for Alaska's Youth

FDA Grants Breakthrough Therapy Designation to Innovative CAR-T Therapy

West Virginia School Board Appeals Vaccine Exemption Ruling to Supreme Court

Doctors' Religious Beliefs Shouldn't Override Patient Care

AI Tool Offers New Hope for Diagnosing Advanced Heart Failure

Amazon Health AI: Your Pocket Doctor for Personalized Care

Mississippi's Dr. Daniel Edney Considered for CDC Directorship

AI Technology Shows Promise in Diagnosing Advanced Heart Failure

The Risks of a Mystic as Public Health Leader